Lance Wehrle
Internal Medicine · Blackfoot, IDNPI 1184919607
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 68 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $323 and has fallen 74.7% since, to $82 in 2025. Among internal medicine clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 68 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$172
- Novartis$152
- Amgen$87
- Xeris Pharmaceuticals, Inc.$79
- Lilly USA, LLC$79
- Abbott$59
- plus $562 from 20 others
What the payments were for
- Food & beverage$1,17899%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 9 | $172 |
| Novartis | 8 | $152 |
| Amgen | 5 | $87 |
| Xeris Pharmaceuticals, Inc. | 4 | $79 |
| Lilly USA, LLC | 6 | $79 |
| Abbott | 3 | $59 |
| Averitas Pharma Inc. | 2 | $58 |
| Novo Nordisk | 4 | $57 |
| Mylan Specialty L.p. | 2 | $44 |
| GSK | 3 | $41 |
| Medtronic | 2 | $40 |
| Dexcom, Inc. | 2 | $39 |
| Merck | 2 | $39 |
| Sunovion Pharmaceuticals Inc. | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Biohaven Pharmaceuticals, Inc. | 2 | $23 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Edwards Lifesciences | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Electromed, Inc. | 1 | $16 |
| Neurelis, Inc. | 1 | $13 |
| Boehringer Ingelheim | 1 | $13 |
| Pfizer | 1 | $12 |
| AstraZeneca | 1 | $12 |
How this compares
$1,190 in reported general payments places this provider in the 90th percentile of 289 internal medicine providers in Idaho.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 187 | $197,667 |
| MounjaroTirzepatide | 103 | $113,893 |
| EliquisApixaban | 87 | $102,994 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $60,124 |
| TrulicityDulaglutide | 62 | $59,321 |
| FarxigaDapagliflozin Propanediol | 60 | $53,966 |
| JardianceEmpagliflozin | 42 | $39,912 |
| Tresiba Flextouch U-100Insulin Degludec | 66 | $36,889 |
| RybelsusSemaglutide | 20 | $30,562 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $26,676 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $20,959 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $20,537 |
| MyrbetriqMirabegron | 22 | $20,282 |
| TradjentaLinagliptin | 11 | $16,772 |
| JanuviaSitagliptin Phosphate | 19 | $12,576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $57 | $228,229207 claims |
| Lilly USA, LLCMounjaro, Trulicity | $79 | $173,213165 claims |
| PfizerEliquis | $12 | $102,99487 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $12 | $74,92585 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $41 | $69,610107 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $13 | $68,79069 claims |
| MerckJanuvia, Dulera | $39 | $16,42231 claims |
| AbbVieLinzess | $172 | $7,81513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 289 internal medicine providers in Idaho.
Other internal medicine in Blackfoot
- Gary UlleryBlackfoot$3K
- Sherwin D'souzaPocatello$543K
- Diana DumitrascuEagle$143K
- Huiling QiBoise$62K
- Aditya SinghPocatello$37K
- Carolyn BridgesBoise$27K
- Susan WachterIdaho Falls$22K
- Ahmed MahmoodIdaho Falls$21K
- Eric BensonPost Falls$19K
- Douglas AndersenPocatello$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.